Ordenar

Buscar

01/11/2024 Comparative Analysis of Classification Criteria in IgG4-Related Disease and Evaluating Diagnostic Accuracy from a Retrospective Cohort in Clinical Practice
Lopez-Gomez, M, Moya-Alvarado, P, Park, HS, Martín, MC, Calleja, S, Codes-Mendez, H, Magallares, B, Castellví, I, Barros-Membrilla, AJ, Laiz, A, Diaz-Torné, C, Sainz, L, Bernárdez, J, Martínez-Martinez, L, Corominas, H. Comparative Analysis of Classification Criteria in IgG4-Related Disease and Evaluating Diagnostic Accuracy from a Retrospective Cohort in Clinical Practice. Diagnostics. 2024; 14(22)DOI:10.3390/diagnostics14222583. PMID:39594249. IF:3.300(Q1/2D).
01/11/2024 Mycobacterium branderi Diagnosed by CryoEBUS. A New Tool for Infection Diagnosis?
Codern, AR, Ruiz, VP, Mitjà, PS. Mycobacterium branderi Diagnosed by CryoEBUS. A New Tool for Infection Diagnosis?. ARCHIVOS DE BRONCONEUMOLOGIA. 2024; 60(11)DOI:10.1016/j.arbres.2024.06.012. PMID:39013726. IF:9.200(Q1/1D).
01/11/2024 Asthma Control According to GINA 2023: Does Changing the Criteria Improve Asthma Control?
Arismendi, E, Ribo, P, Garcia, A, Torrego, A, Bobolea, I, Casas-Saucedo, R, Palomino, R, Picado, C, Muñoz-Cano, R, Valero, A. Asthma Control According to GINA 2023: Does Changing the Criteria Improve Asthma Control?. Journal of Clinical Medicine. 2024; 13(22)DOI:10.3390/jcm13226646. PMID:39597790. IF:2.900(Q1/2D).
01/11/2024 Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
Caballero-Borrego, M, Piedra, A, Gallego, O, López-Pousa, A, Castillo, P, Navarrete, P, Prat, A, Grau, JJ. Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Brazilian Journal of Otorhinolaryngology. 2024; 90(6)DOI:10.1016/j.bjorl.2024.101493. PMID:39205362. IF:1.800(Q2/4D).
01/11/2024 Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study
Krebs, MG, Forster, M, Majem, M, Peguero, J, Iams, W, Clay, T, Roxburgh, P, Doger, B, Bajaj, P, Barba, A, Perera, S, Mueller, C, Triebel, F. Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study. Jto Clinical And Research Reports. 2024; 5(11)DOI:10.1016/j.jtocrr.2024.100725. PMID:39403626. IF:(Q/D).
01/11/2024 Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial
Provencio, M, Nadal, E, Insa, A, Campelo, RG, Casal, J, Dómine, M, Massuti, B, Majem, M, Rodríguez-Abreu, D, Martínez-Marti, A, de Castro, J, de Antonio, DG, Macia, I, Figueroa, S, Vago, LF, Calvo, V, Palmero, R, Sierra-Rodero, B, Martínez-Toledo, C, Molina-Alejandre, M, Serna-Blasco, R, Romero, A, Cruz-Bermúdez, A. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. LANCET ONCOLOGY. 2024; 25(11)DOI:10.1016/S1470-2045(24)00498-4. PMID:39419061. IF:35.900(Q1/1D).
01/11/2024 Recommendations on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Patient Selection
Borque-Fernando, A, Zapatero, A, Manneh, R, Alonso-Gordoa, T, Couñago, F, Domínguez-Esteban, M, López-Valcárcel, M, Rodríguez-Antolín, A, Sala-González, N, Sanmamed, N, Maroto, P. Recommendations on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Patient Selection. Actas Urologicas Espanolas. 2024; 48(9)DOI:10.1016/j.acuro.2024.03.002. PMID:38740263. IF:1.200(Q3/7D).
01/11/2024 Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3
Gray, JE, Markovets, A, Reungwetwattana, T, Majem, M, Nogami, N, Peled, N, Lee, JS, Cho, BC, Chewaskulyong, B, John, T, Han, JY, Sebastian, M, Todd, A, Rukazenkov, Y, Barrett, C, Chmielecki, J, Lee, SM, Ramalingam, SS, Hartmaier, R. Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3. Journal of Thoracic Oncology. 2024; 19(11)DOI:10.1016/j.jtho.2024.07.008. PMID:39029876. IF:20.800(Q1/1D).